Our findings demonstrate the oncogenic role of METTL1 and the pathological significance of the METTL1‐m7G‐EGFR/EFEMP1 axis in BC development, thus providing potential therapeutic targets for the BC treatment. This evidence concerns the gene EFEMP1 and breast cancer.